Health 24 April 2026 - 23 May 2026

Ocugen Shares Flat Ahead of Holiday-Shortened Week for Eye-Therapy Bid
···

Ocugen Shares Flat Ahead of Holiday-Shortened Week for Eye-Therapy Bid

Ocugen shares closed Friday at $1.34 with 3.9 million shares traded, little changed ahead of the Memorial Day break. The company recently closed a $130 million convertible note sale, using $32.7 million to repay debt and reserving the rest for general purposes. Ocugen will present at the Stifel 2026 Virtual Ophthalmology Forum on Tuesday. The company has completed enrollment in two late-stage eye-disease programs.
May 24, 2026
AAPG Shares Bounce Ahead of ASCO, Investors Eye Drug Results
···

AAPG Shares Bounce Ahead of ASCO, Investors Eye Drug Results

Ascentage Pharma’s U.S.-listed shares closed at $21.01 Friday, up 1.69%, after hitting a 52-week low of $18.56 earlier in the week. The rebound followed the release of new ASCO 2026 clinical data on olverembatinib, lisaftoclax, and alrizomadlin. Nasdaq is closed for Memorial Day on Monday. The stock remains about 57% below its 52-week high.
May 23, 2026
Larimar Shares Fall, FDA Submission Seen as Next Hurdle
····

Larimar Shares Fall, FDA Submission Seen as Next Hurdle

Larimar Therapeutics shares fell 3.36% to $3.45 Friday as investors awaited a planned June start to its rolling FDA application for nomlabofusp, a protein-replacement drug for Friedreich’s ataxia. The company ended March with $200.4 million in cash and projected funding into Q2 2027. Shareholders approved raising authorized common shares to 215 million. The FDA has approved only one other FA treatment to date.
May 22, 2026
GPCR Stock Jumps As Obesity-Drug Race Gets A New Twist
···

GPCR Stock Jumps As Obesity-Drug Race Gets A New Twist

Structure Therapeutics shares climbed 5.3% to $38.79 in late New York trading Thursday, with no new company release in the past two days. The move followed Eli Lilly’s report of strong weight-loss data for its obesity drug, which kept focus on the sector. Structure’s aleniglipron showed 16.3% placebo-adjusted mean weight loss at 44 weeks in Phase 2. Monashee Investment Management trimmed its stake in the first quarter, SEC filings show.
May 21, 2026
Aimei Health: Nasdaq Sends AFJK 60-Day Notice
···

Aimei Health: Nasdaq Sends AFJK 60-Day Notice

Aimei Health received a Nasdaq deficiency notice after missing the May 15 deadline for its March-quarter 10-Q filing. Shares traded at $42.18 in pre-market activity ahead of Thursday’s U.S. session. The company has 60 days from the May 19 notice to regain compliance or risk delisting. Aimei is also seeking to complete a merger with United Hydrogen Group, pending regulatory approval.
May 21, 2026
Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear
···

Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear

Neurogene Inc. shares closed at $26.95 Wednesday, up 0.3%, with little movement before Thursday’s Nasdaq open. About 90% of participants have been dosed in the registrational Embolden trial for NGN-401, with completion expected in Q2. Neurogene reported $243.2 million in cash as of March 31, enough to fund operations into early 2028. The company’s latest filings were posted May 12, with no new updates since.
May 21, 2026
Jaguar Health Shares Spike After 816% Revenue Jump, But Trial Results Still Key
···

Jaguar Health Shares Spike After 816% Revenue Jump, But Trial Results Still Key

Jaguar Health shares rose 9.2% to $3.67 Wednesday after first-quarter revenue jumped to $20.3 million, mainly from a U.S. licensing deal for Mytesi and Canalevia-CA1. Trading volume surged to 593,152 shares. Net loss narrowed to $7.0 million from $10.5 million a year earlier. The company’s crofelemer rare-disease trial advanced with its first pediatric patient entering an extension phase.
May 21, 2026
BAT’s Velo Bet Faces a Fresh WHO Warning After Shares Hit a 52-Week High
···

BAT’s Velo Bet Faces a Fresh WHO Warning After Shares Hit a 52-Week High

The World Health Organization on Friday called for tighter controls on nicotine pouches, citing risks to youth, just after British American Tobacco shares hit a 52-week high. BAT stock climbed 3.22% Thursday, then slipped 1.67% Friday morning. The U.S. FDA this week eased enforcement on some nicotine products, boosting tobacco shares. WHO said about 160 countries lack specific regulations for pouches.
May 15, 2026
BAT shares extend rally as FDA shift gives Vuse and Velo a cleaner U.S. read
···

BAT shares extend rally as FDA shift gives Vuse and Velo a cleaner U.S. read

British American Tobacco shares rose 1.72% to GBX 4,713.78 in London Wednesday, building on a 5.82% gain after the FDA eased enforcement on some e-cigarette and nicotine pouch products with pending applications. A U.S. judge also dismissed BAT’s North Korea sanctions case after the company paid $630 million in penalties. Philip Morris and Altria shares also moved on the FDA news.
May 13, 2026
Valneva’s Brazil Vaccine Green Light Comes With a Stock-Market Catch
···

Valneva’s Brazil Vaccine Green Light Comes With a Stock-Market Catch

Brazil’s Anvisa has authorized Instituto Butantan to manufacture Valneva’s chikungunya vaccine locally, shifting production from France. The vaccine, branded Butantan-Chik, is cleared for adults 18–59 and may enter Brazil’s public health system. Valneva shares fell 7.6% in Paris ahead of its Q1 results. Chikungunya caused over 127,000 cases and 125 deaths in Brazil in 2025.
May 12, 2026
Reckitt Benckiser Group plc Hit by Fresh Profit Slump as Dettol Owner’s Margin Test Deepens
···

Reckitt Benckiser Group plc Hit by Fresh Profit Slump as Dettol Owner’s Margin Test Deepens

Reckitt Benckiser’s Bangladesh unit posted a 28.31% drop in first-quarter profit to Tk10.99 crore, with revenue down to Tk132.61 crore from Tk147.34 crore. Earnings per share fell to Tk23.26 from Tk32.45. Parent company sales growth missed analyst expectations, and first-half margins are forecast to be two percentage points lower than last year. Demand for hygiene brands in Bangladesh has eased since the pandemic.
May 4, 2026
British American Tobacco p.l.c. Faces Fresh UK Smoking Ban Test After Royal Assent
···

British American Tobacco p.l.c. Faces Fresh UK Smoking Ban Test After Royal Assent

Britain’s Tobacco and Vapes Bill became law April 29, banning tobacco sales to anyone born on or after Jan. 1, 2009. British American Tobacco shares rose 1.5% to 4,323 pence in London Thursday. The law increases pressure on BAT’s cigarette business as it shifts focus to vapes and nicotine pouches. The act also gives ministers new powers to restrict vape marketing and packaging.
April 30, 2026
CSL Shares Bounce After Buyback Tops 6 Million, But Pentagon Flu Vaccine Shock Lingers
···

CSL Shares Bounce After Buyback Tops 6 Million, But Pentagon Flu Vaccine Shock Lingers

CSL Limited has repurchased over 6 million shares for about A$1.024 billion as of Monday, amid a sharp stock decline and ongoing buyback program. The company’s shares closed at A$131.82, just above last week’s 52-week low, after the U.S. scrapped its military flu vaccine mandate, affecting CSL’s key Seqirus unit. Half-year profit fell 81% to US$401 million. Gordon Naylor was named interim CEO in February.
April 27, 2026
Aviva plc Extends Menopause Support to 675,000 More Customers as Health Cover Competition Tightens
···

Aviva plc Extends Menopause Support to 675,000 More Customers as Health Cover Competition Tightens

Aviva will extend specialist menopause support to over 675,000 additional private medical insurance customers and families via its Digital GP service. The insurer bought 931,432 shares for cancellation on April 24 as part of its buyback programme. Aviva shares traded at 626.80 pence, down 0.32%, at 17:25 BST Monday. The company’s AGM is set for May 6, with a trading update and dividend payment scheduled for May 14.
April 27, 2026
British American Tobacco Stock Slips as UK Smoking Ban Nears Law and BAT Keeps Buyback Running
···

British American Tobacco Stock Slips as UK Smoking Ban Nears Law and BAT Keeps Buyback Running

British American Tobacco faces a UK regulatory test as Britain’s lifetime smoking ban is set to become law, barring anyone born after January 1, 2009, from ever buying cigarettes. BAT shares fell 1.26% to 4,248 pence on Monday. The company bought back 260,511 shares last week and plans to cancel them. Smokeless products made up 18.2% of BAT’s revenue in February, with 34.1 million consumers reported.
April 27, 2026
CSL Shares Near Nine-Year Low After Pentagon Flu Shot U-Turn Tests Buyback
···

CSL Shares Near Nine-Year Low After Pentagon Flu Shot U-Turn Tests Buyback

CSL shares closed at A$130 on Friday, near a nine-year low, after the U.S. military made annual flu shots voluntary, raising concerns over CSL Seqirus’s vaccine sales. The company disclosed a A$13.1 million share buyback on April 23. U.S. military flu vaccine uptake had been a key channel for Seqirus. CSL reported a 4% drop in first-half revenue and kept its 2026 growth guidance.
April 24, 2026
1 2 3 … 5

Stock Market Today

  • DroneShield ASX:DRO Valuation Examined Amid ASIC Governance Probe
    May 24, 2026, 10:03 AM EDT. DroneShield (ASX:DRO) faces a formal probe by the Australian Securities and Investments Commission (ASIC) into its November 2025 disclosures and share trading, raising governance concerns. The stock gained 1% in one day but fell 18.6% over 30 days, despite a 151.5% total shareholder return over the past year. Trading at A$3.03, it stands 28% below analyst price targets, with a price-to-sales (P/S) ratio of 12.9x, exceeding sector averages. Analysts debate its valuation, with some seeing a fair value of A$8.57 based on recurring institutional contracts, while others caution on risks including procurement delays. Investors are advised to weigh growth potential against regulatory risks amid global defense spending expansion.